Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2020)

Monopar Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 2260750.0 for Q4 2020.

  • For Q4 2020, Income from Continuing Operations fell 84.57% year-over-year to 2260750.0; the TTM value through Dec 2020 reached 6508875.0, down 50.54%, while the annual FY2024 figure was 15757701.0, 87.54% down from the prior year.
  • Income from Continuing Operations for Q4 2020 was 2260750.0 at Monopar Therapeutics, down from 1647979.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 373839.0 in Q1 2017 and bottomed at 14897531.0 in Q3 2017.
  • The 4-year median for Income from Continuing Operations is 929233.5 (2018), against an average of 1922931.88.
  • The largest YoY upside for Income from Continuing Operations was 94.36% in 2018 against a maximum downside of 140.01% in 2018.
  • A 4-year view of Income from Continuing Operations shows it stood at 736800.0 in 2017, then dropped by 25.73% to 926358.0 in 2018, then plummeted by 32.23% to 1224895.0 in 2019, then plummeted by 84.57% to 2260750.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Income from Continuing Operations are 2260750.0 (Q4 2020), 1647979.0 (Q3 2020), and 1464132.0 (Q2 2020).